State-level cannabis reforms have exposed the inability of the United States to abide by the terms of the legal bedrock of the global drug control system. It is calls for a conversation the US federal government wishes to avoid. The result is a new official position on the UN drugs treaties that, despite its seductively progressive tone, serves only to sustain the status quo and may cause damage beyond drug policy.
The United Nations General Assembly Special Session (UNGASS) on drugs in 2016 is intended to provide states with the opportunity to openly debate the future of international drug policies. An event at UN headquarters in New York discussed precisely what preparations are necessary to make sure the UNGASS accomplishes this objective.
David Bewley Taylor is the founding Director of the Global Drug Policy Observatory at Swansea University, UK. He has been researching various aspects of drug policy for over twenty years with his main areas of interest being US drug policy, the UN and international drug policy and more recently counter narcotics strategies in Afghanistan....
David Bewley-Taylor, Martin Jelsma, Christopher Hallam
16 June 2014
Scheduling is mostly prioritised in its repressive pole, though present debates are increasingly highlighting the need to modify the balance of the system in order to affirm the importance of the principle of health.
In March 2014, country delegations will gather at the United Nations Commission on Narcotic Drugs (CND) to review progress and challenges in international drug control since the agreement of a Political Declaration on drugs in 2009. Given that the Political Declaration aims to “eliminate or reduce significantly” the use, supply and demand of controlled drugs by 2019, this meeting represents an important opportunity for honest evaluation and an acknowledgement that these targets are not being achieved. With a United Nations General Assembly Special Session (UNGASS) on drugs just two years away, this is an important time for international drug control policy.
Ahead of the High-Level Segment on the world drug problem to take place on 13th and 14th January 2014, the UNODC Executive Director, Yuri Fedotov, has released his "contributions" to the debate. This 19-page document is, in parts, refreshingly honest about the “unequal” progress that has been made since 2009 (with reductions in supply or demand for some drugs in some places being offset by increases elsewhere), the setbacks and new challenges, and the fact that “the overall magnitude of drug demand has not substantially changed at the global level”.